Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. A Blinc
“Aspirin resistance”, defined as an inadequate suppression of platelet thromboxane production or an inadequate inhibition of platelet aggregation in vitro from low-dose aspirin, has been linked to a several-fold increased risk of recurrent atherothrombotic events among patients at high risk. However, in view of its multifactorial causes and non-standardised methodology of detection, aspirin resistance still lacks a generally accepted definition and has unclear clinical implications.
Failure of aspirin to suppress platelet thromboxane production or to inhibit platelet aggregation in vitro has been convincingly linked to an inadequate protection against atherothrombotic events. However, “aspirin resistance”, also called “aspirin non-responsiveness” or simply “treatment failure”, is a heterogeneous phenomenon, still without a generally accepted definition and with unclear clinical implications. It has been described in a variable proportion of patients with atherothrombotic diseases, i.e., up to a quarter of patients with stable coronary disease, about a third of patients with stroke, and up to 40-60% in patients with peripheral arterial disease. How should practicing physicians respond to the increasing abundance of news regarding aspirin resistance?
The most important cardiovascular effect of aspirin is mediated by irreversible inhibition of platelet cyclooxigenase-1 (COX-1) resulting in the suppression of thromboxane (TX) A2 production. However, this does not completely inhibit the platelet function, since release of TX A2 is only one of several amplification mechanisms in platelet activation leading to the formation of stable aggregates. In other words, even a perfect response to aspirin does not offer complete clinical protection against atherothrombotic events. In patients at high risk, treatment with low dose aspirin offers an overall 20 – 25 % reduction in major vascular events, but large differences in the level of cardiovascular protection have been described between aspirin responders and non-responders. Non-responders with a previous ischemic stroke had a 9-fold increase in recurrent ischemic events in comparison to aspirin responders (1), non-responders among coronary artery patients were about 3 times more likely to die, suffer a myocardial infarction or a cerebrovascular accident (2), and non-responders among peripheral vascular patients had an almost doubled rate of peripheral artery reocclusion after angioplasty (3). In a substudy of the HOPE trial, patients in the highest quartile of urinary excretion of 11-dehydroTX B2, i.e., aspirin-non-responders, were 3.5-times more likely to die than those in the lowest quartile, i.e., aspirin-responders (4). In spite of the growing evidence of harm caused by non-responsiveness to aspirin, experts remain cautious and urge for further studies, mainly because criteria for abnormal responses have not been clearly defined and correlated with clinical outcomes (5). The effects of aspirin on platelet function can be tested with in vitro platelet aggregation essays or by measuring platelet TX production, yet no method is ideal. Optical aggregation essays using platelet rich plasma are time-honored tests, but are quite labor-intensive and impractical for routine use. The simple whole blood test with PFA-100 (Platelet Function Analyser, Dade Behring) which measures “closure time”, i.e., the time of formation of a stable platelet plug on an agonist-coated membrane exposed to rapid blood flow, has shown rather poor agreement with optical aggregation measurements (6), and in patients with stable coronary artery disease the risk of atherothrombotic events and death was related only to aspirin-resistance as determined optical aggregometry (2). Even measuring platelet TX formation is not without flaws. Measurements of TX metabolites in urine reflect TX production in platelet and non-platelet sources, i.e., macrophages, including those in atherosclerotic plaques. By combining optical platelet aggregation tests with TX production measurements aspirin resistance may be categorised into the pharmacokinetic type, the pharmacodynamic type and “pseudoresistance” where TX-independent mechanisms of platelet aggregation play a major role (Table 1) (7). Some possible causes of aspirin resistance are listed in Table 2.
Response to oral aspirin
Response to aspirin added in vitro
Collagen-induced platelet aggregation inhibited
Platelet thromboxane production inhibited
Pharmacokinetic type resistance
Pharmacodynamic type resistance
“Pseudoresistance” to aspirin
How should aspirin resistance be approached in the clinical setting? At present, the European expert consensus on the use of antiplatelet drugs does not recommend assessing the antiplatelet effect of aspirin in the individual patient (8). Since atherothrombosis is a multifactorial disease, comprehensive cardiovascular disease prevention should be practiced without relying exclusively on one type of pharmacologic intervention. Treatment failures occur with every drug, including clopidogel that has failed to suppress platelet aggregation in up to a quarter of patients with acute myocardial infarction which, in turn, has increased the subject’s risk for recurrent atherothrombotic events (9). Regarding the use of clopidogrel and combined antiplatelet therapy, current guidelines should be followed. Increasing the dose of aspirin over the low-dose range is unlikely to overcome the pharmacodynamic type of resistance and “pseudoresistance” to aspirin, but definitely escalates the risk of bleeding. At present, it seems that the most reliable strategy to prevent aspirin treatment failure is promoting patient compliance with low-dose aspirin and avoiding concurrent use of non-steroidal anti-inflammatory drugs. However, we are eagerly waiting for reliable tests of platelet function that would be clinically helpful in screening for aspirin resistance among the most vulnerable population, i.e., patients with advanced multifocal atherosclerosis, including those with peripheral arterial disease.
1- Pharmacokinetic type resistance
3-“Pseudoresistance” to aspirin (= TX- independent platelet aggregation)
* Polymorphisms resulting in an impaired interaction between aspirin and platelet COX-1 are an attractive hypothesis, but so far no known genotype in humans is associated with aspirin resistance and one polymorphism actually improves the sensitivity of COX-1 to aspirin (11).
** It is unlikely that aspirin resistance would be caused by an increase in the inducible platelet COX-2 isoform in platelets because in the clinical setting, COX-2-selective inhibitors have not suppressed aspirin-resistant platelet TX A2 formation. In fact, they have recently shown harmful cardiovascular effects.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year-follow-up of aspirin-responder and aspirin non-responder. A pilot study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8236166
2. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12651041
3. Mueller RM, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Mittlboeck M, Schreiner W, Losert U, Wolner E. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9308744
4. Eikelboom JW, Hirsch J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death among patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11940542
5. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1: 1710-13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12911581
6. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed
7. Weber A-A, Przytulski B, Schanz A, Hohlfeld T, Schrör K. Towards a definition of aspirin resistance: a typological approach. Platelets 2002; 13: 37-40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11918835
8. The Task Force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. Eur Heart J 2004; 25: 166-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14720534
9. Matetzky S, Shenkman B, Guetta V, Schechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3064-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15184279
10. DeGaetano G, Cerletti C. Aspirin resistance: a revival of platelet aggregation tests? J Thromb Haemost 2003; 1: 1710-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12941050
11. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003; 73: 122-30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12545150
© 2017 European Society of Cardiology. All rights reserved